Current status: Answered by Humza Yousaf on 20 September 2022
To ask the Scottish Government, in light of the reported progress of the Lyme disease vaccine candidate VLA15 being developed by Pfizer and Valneva, what support it is giving to the development of this vaccine.
The Lyme disease vaccine candidate VLA15 was developed in Austria and, as such, is not directly supported by Scottish funding. The Scottish Government is however regarded as preferred customers for Valneva, and should the decision be taken to procure Lyme Disease vaccines from Valneva, the Scottish Government will receive preferential access and pricing. This is in recognition of the support provided to Valneva by Scotland.
Scottish Enterprise have supported Valneva Livingston with funding packages for the following vaccines, all of which have received grant support: